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Summary
BACKGROUND: There has been much discussion about
coronavirus disease 2019 (COVID-19) and the virus that
causes it, severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) in children and adolescents, since the
pandemic was recognised in early 2020. Understanding
their role in this pandemic is important for the development
of appropriate prevention measures.
OBJECTIVE: To summarise evidence about three aspects
of SARS-CoV-2 and COVID-19 in children and adoles-
cents: (1) severity of SARS-CoV-2 presentation, (2) risk of
SARS-CoV-2 infection and (3) risk of transmitting SARS-
CoV-2.
METHODS: We searched PubMed and MedRxiv for stud-
ies on SARS-CoV-2 and COVID-19 in children and ado-
lescents from January 2020 to 21 January 2021. The elec-
tronic search was supplemented by papers found in a
manual search or suggested by experts up to 29 March
2021. We included case reports, cross-sectional studies,
cohort studies, narrative reviews or viewpoints, systematic
reviews and modelling studies. We synthesised the infor-
mation descriptively and attempted to report findings sep-
arately for: infants and small children (0–5 years) who are
mostly pre-school; school children (6–12 years) broadly
covering primary school years; and adolescents (13–17
years).
RESULTS: Of 2778 screened articles, we included 63 (20
case reports, 18 cross-sectional studies, 8 cohort stud-
ies, 6 narrative reviews or viewpoints, 10 systematic re-
views and 1 modelling study). Children (≤12 years of age)
and adolescents (13–17 years of age) usually present with
mild disease, with few requiring intensive care treatment.
A minority of children of all ages (<18 years) remains
asymptomatic throughout the course of infection. In sero-
logical studies, reported symptoms are similar in children
with and without SARS-CoV-2 antibodies. Children and
adolescents can acquire and transmit SARS-CoV-2. The
risks of acquiring and transmitting SARS-CoV-2 seems to
increase with age. There was limited information about
SARS-CoV-2 variants of concern. Poor reporting of age
groups and contextual factors such as levels of community
transmission, school closures and other non-pharmaceu-
tical interventions make synthesis of findings across stud-
ies difficult.
CONCLUSIONS: The clinical presentation and role of chil-
dren and adolescents in SARS-CoV-2 susceptibility and
transmission needs further investigation, particularly with
regard to variants of concern. Large, prospective studies
that attempt to minimise biases in design, are analysed
appropriately and reported comprehensively should be
conducted.
Introduction
There has been much discussion about coronavirus disease
2019 (COVID-19) and the virus that causes it, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in
children and adolescents, since the pandemic was recog-
nised in early 2020 [1–3]. Early in 2020, many countries
imposed general lockdowns to limit the spread of the virus
and to reduce the risk of collapse of their health systems,
which included the closure of educational facilities (day
care, schools and higher education institutions). The clo-
sures resulted in large numbers of children not attending
school worldwide, with greater reported impacts on stu-
dents from more disadvantaged socioeconomic back-
grounds [4, 5].
The earliest reports of COVID-19 included small numbers
of children and adolescents and commentaries suggested
that children were “spared the major impact of COVID-19
virus” [6]. Their role in the transmission of SARS-CoV-2
was unclear, however, because children were tested less
frequently than adults and differences in lockdown restric-
tions affect the contact patterns and exposure of children
and adults differently [7]. In spring 2020, the Federal Of-
fice of Public Health asked the Swiss National COVID-19
Science Task Force to provide information about SARS-











Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)”.
No commercial reuse without permission. See https://smw.ch/permissions
Page 1 of 13
form the development of preventive measures. This re-
quest led to a rapid review of the literature, which has since
been updated four times and published on the website of
the Swiss National COVID-19 Science Task Force most
recently on 28 April 2021 [8]. This article is based on the
rapid review and aims to summarise evidence about three
aspects of SARS-CoV-2 and COVID-19 in children and
adolescents: (1) severity of SARS-CoV-2 presentation in
children and adolescents; (2) risk of SARS-CoV-2 infec-
tion in children and adolescents; and (3) risk of children
and adolescents transmitting SARS-CoV-2. In addition, we
tried to identify studies about SARS-CoV-2 variants of
concern, which were documented to have started to emerge
in autumn 2020 [9].
Methods
This review began as a rapid review of literature selected
from a systematic search, with updates conducted as the
volume of publications increased. Owing to the urgent sit-
uation in early 2020, we did not write a protocol or register
the review.
Search strategy
We searched for literature published since 1 January 2020
in two electronic databases (PubMed and MedRxiv). We
conducted the first search on 1 May 2020 and the last
search on 21 January 2021. We used the following com-
binations of search terms in PubMed for title and abstract:
(COVID-19 OR "SARS-CoV-2" OR "novel coronavirus")
AND ("attack rate" OR "secondary attack rate" OR "in-
fectiousness" OR "transmission rate" OR "transmission")
AND (children OR "pediatric patients"), and
("COVID-19" OR "SARS-CoV-2" OR "novel coron-
avirus") AND ("asymptomatic" OR "presymptomatic")
AND ("attack rate" OR "secondary attack rate" OR "in-
fectiousness" OR "transmission rate" OR "transmission"
OR "viral shedding") and (COVID-19 OR "SARS-CoV-2"
OR "novel coronavirus") AND ("attack rate" OR "sec-
ondary attack rate" OR "infectiousness" OR "transmission
rate" OR "transmission") AND (children OR "pediatric
patients") AND (kindergarten OR crèche OR creche OR
preschool OR "elementary school" OR "secondary school"
OR "high school"). In MedRxiv we searched separately
for "COVID-19 and attack rate", "COVID-19 and infec-
tiousness" and "COVID-19 and children". We supplement-
ed the search results with a non-systematic search on 29
March 2021 of papers identified through general reading,
in e-mail alerts, suggested by experts, or referenced in the
aforementioned literature search. We searched, in particu-
lar, for studies that reported on variants of concern in chil-
dren and adolescents. Only studies in German and English
were included in the review.
Study selection
Case reports, cross-sectional studies, cohort studies, narra-
tive and systematic reviews and modelling studies were el-
igible for inclusion. One reviewer (MW) screened the ti-
tles and abstracts of all identified articles and read the full
text of all those potentially eligible. We did not include all
identified articles that might have been relevant throughout
the search period because of redundancy. For example, if
many review articles reported on the same original studies,
we include the more recent reviews.
Data extraction
MW extracted and recorded relevant scientific information
from the selected studies. For each included study, MW
and MG extracted the details of: author and publication
year, country, study design, number and age range of in-
cluded study participants, a summary of the study setting
and, for review articles, the number of included studies.
Risk of bias
We did not use a specific tool for assessment of the risk of
bias owing to the urgency of the situation at the start of the
pandemic. We considered both study quality and the risk
of possible biases when reading the studies included in this
review, and reported these in the results section.
Data synthesis
We synthesised information from the included studies de-
scriptively. We did not perform quantitative syntheses be-
cause, for the objectives of the review, we judged that
the study designs, study settings and ages of participants
would be too heterogeneous for pooling of results to be ap-
propriate.
The findings for the three review questions might differ by
age, so we tried to summarise the findings for different age
categories when data were available, which would make
practical sense in Switzerland. We defined these groups as:
infants and small children (0–5 years) who are mostly pre-
school; school children (6–12 years) broadly covering pri-
mary school years; and adolescents (13–17 years).
Results
In total, we screened 2778 studies published up to 21 Janu-
ary 2021, of which 29 were included. We included another
34 studies (23 published, 11 not published and/or not peer-
reviewed) identified up to 29 March 2021. Of these 63 ar-
ticles, there were 20 case reports, 18 cross-sectional stud-
ies, 8 cohort studies, 6 narrative reviews or viewpoints, 10
systematic reviews and 1 modelling study (fig. 1). We re-
port findings from articles published up to 29 March 2021
in the results section. We summarise more recent develop-
ments in the discussion section.
Severity of SARS-CoV-2 presentation in children and
adolescents
Paediatric SARS-CoV-2 cases were described from the
early beginnings of the pandemic, but children (≤12 years
of age) and adolescents (13–17 years of age) usually pre-
sent with mild disease, with few requiring intensive care
treatment [6, 10–15]. The reasons for the comparatively
mild disease, as well as the risk factors for severe disease
and potential mid-term to long-term effects on SARS-
CoV-2 infection in children and partially in adolescents,
are still being investigated.
Asymptomatic SARS-CoV-2 presentation in children and
adolescents
An asymptomatic course of disease is relevant for public
health if the infected people are infectious, go undetected
and can transmit SARS-CoV-2. A systematic review of
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studies published up to 10 June 2020 provides information
about the proportions of children of all ages, adolescents
and adults who were followed through the course of in-
fection. Most studies that distinguished participants by age
were done in hospital settings, which might result in se-
lection bias that underestimates the proportion of asymp-
tomatic infections. The children in hospital-based studies
were generally diagnosed during investigations of house-
hold contacts of confirmed cases and were hospitalised for
observation. In both adults and children, the majority of in-
dividuals with SARS-CoV-2 developed symptomatic dis-
ease. The proportions with persistently asymptomatic in-
fection were 27% in children (95% confidence interval
[CI] 22–32%; 10 studies, 285 children) and 11% in adults
(95% CI 6–19%; 10 studies, 3228 adults) [16]. Most stud-
ies in this review did not give detailed information about
age, so it was not possible to examine differences between
children of different age groups.
Asymptomatic infections can also be estimated in sero-
prevalence studies, although bias in recalling mild symp-
toms over periods of several months might result in under-
recording and symptoms reported cannot be attributed to a
particular infection episode. In the SEROCoV-POP study,
which included randomly selected participants from a past
cohort study and their household members in Geneva,
Switzerland, 13% (77/590) of all participants with SARS-
CoV-2 antibodies detected between 6 April and 30 June
2020 did not recall any SARS-CoV-2 symptoms since Jan-
uary 2020. When stratified by age, 44% (4/9) aged 4–9
years, 26% (13/50) aged 10–17 years and 10% (28/278)
aged 18–49 years reported no symptoms [17]. With the ex-
ception of loss of taste or smell, symptoms were as com-
mon in seropositive as in seronegative children. In the Ciao
Corona study in Zurich, a cohort study of 273 classes in
55 schools (n = 2585), 73% of all children (age range 6–16
years) experienced symptoms compatible with a SARS-
CoV-2 infection between January and June 2020, with no
difference between seropositive and seronegative children
[18]. Between July and November 2020, when the study
analysed 2831 children from 275 classes in 55 schools, on-
ly 29% (29/101) of seropositive children and 22% (420/
1923) of seronegative children reported symptoms com-
patible with SARS-CoV-2 [19].
Figure 1: Study selection. 1 Eligibility: language (English, Ger-
man); study design (case reports, cross-sectional studies, cohort
studies, modelling studies, reviews/viewpoints; both preprints and
peer-reviewed studies; study population (children and adolescents
<18 years old); settings (households, schools / day care centres /
camps, community)
We did not find any studies reporting the frequency of
asymptomatic paediatric SARS-CoV-2 infection caused by
SARS-CoV-2 variants of concern.
Potential risk factors for severe SARS-CoV-2 disease in
children and adolescents
Early reports suggested especially infants (≤1 year of age)
and younger children (1–5 years of age) to be at a higher
risk of severe disease than older children [13, 20]. These
reports, however, have methodological limitations, such as
some COVID-19 diagnoses being based on clinical symp-
toms alone without performing laboratory tests [13], or
missing data on hospitalisation status [20]. Several nar-
rative reviews, describing 32 different cases of neonatal
SARS-CoV-2 infection in total, all show neonates mostly
presenting with mild disease [21–25]. The respiratory
symptoms described in some patients were generally con-
sistent with their gestational age and could thus not be
attributed to SARS-CoV-2. These findings are supported
by small additional retrospective studies [26, 27] and a
prospective national cohort study from the UK [28], de-
scribing mild SARS-CoV-2 disease progression in
neonates. Multicentre hospital-based studies with more
complete data and consistent case definitions have also
been conducted. A prospective cohort study from 260 hos-
pitals in the UK, following 651 children and young adults
(225/651 <1 year old) between 17 January and 3 July
2020, found that the risk of admission to intensive care
was associated with age <1 month (odds ratio [OR] 3.21,
95% CI1.36–7.66) and age 10–14 years (OR 3.23, 95%
CI 1.55–6.99), compared with a baseline of 15–19 year
olds [29]. Multiple small studies from around the world de-
scribe mild SARS-CoV-2 disease progression and low hos-
pitalisation rates, even in children with severe underlying
health conditions such as cancer and immunosuppression
[30–36].
A hyperinflammatory syndrome in children with
COVID-19, called paediatric inflammatory multisystem
syndrome temporally associated with SARS-CoV-2
(PIMS-TS) in Europe and multisystem inflammatory syn-
drome in children (MIS-C) in the United States has been
described as a serious, but rare consequence of SARS-
CoV-2 infection. The first case of an infant presenting
with classic Kawasaki disease who also tested positive
for SARS-CoV-2 was reported in April 2020 [37]. Shortly
thereafter, researchers in south-east England reported a
cluster of eight children with features associated with
Kawasaki disease or toxic shock syndromes, most of
whom had a history of exposure to, or a positive test for
SARS-CoV-2 [38]. In a report of 99 cases diagnosed with
MIS-C from New York there were 31 in 0–5 year olds, 42
in 6–12 year olds and 26 in 13–20 year olds [39]. Presenta-
tion with any Kawasaki type symptoms was more common
in those aged 0–12 years (31/73, 42%) than in those aged
13–20 years (3/26, 12%).
Potential mid-term and long-term effects of SARS-CoV-2
disease in children and adolescents
By the end of the search period, preliminary data from a
small study in Italy found that children are at risk of long-
term effects in the form of ongoing symptoms referred to
as long COVID or post-acute sequelae of SARS-CoV-2 in-
fection [40].
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Risk of SARS-CoV-2 infection in children and adoles-
cents
The risk of SARS-CoV-2 infection at different ages has
been investigated in different study types. We describe
the findings from population-based/cross-sectional studies,
contact tracing/ household studies and seroprevalence
studies separately because there are risks of bias associated
with different study designs.
Population studies / cross-sectional studies
There were few population-based or cross-sectional studies
available for analysis. An early study, conducted at the be-
ginning of the COVID-19 pandemic in the town of Vo’
in Italy by Lavezzo et al. (2020) tested a majority of the
population (85.9% at the first stage, 71.5% 14 days later)
for SARS-CoV-2, irrespective of symptoms. There were
no cases in 217 children aged 0–10 years and three cases in
250 11–20 year olds (1.2%), compared with 1.1% to 6.0%
in adults in 10-year age bands [41]. This survey is at low
risk of bias because nearly all residents were tested, there
were no restrictions before the lockdown and children and
adults lived in the same households. The COVID-19 In-
fection Survey (CIS), where randomly selected members
of the British population aged 2 years and older submit re-
peated swabs for SARS-CoV-2 testing, reported greater in-
creases in SARS-CoV-2 positivity in children aged 2 to 24
years than in older adults, coinciding with school reopen-
ings in September 2020 [42].
Contact tracing / household studies
We identified three systematic reviews covering contact
tracing / household studies. Viner et al. (2020) included 18
contact tracing studies in any setting, up to 28 July 2020.
They found a lower risk of infection for younger children
<10 years of age (OR 0.52, 95% CI 0.33–0.82) than for
adults (reference group) but not for older children and ado-
lescents >10 years of age (OR 0.72, 95% CI 0.46–1.10)
[43]. Zhu et al. (2020) reported similar findings in 14
household studies up to 24 August 2020 (4 of which were
included by Viner et al. (2020)). The risk of infection
was lower among all <18-year-olds than in adults (relative
risk [RR] 0.62, 95% CI 0.42–0.91) [44]. Madewell et al.
(2020) analysed 15 household studies up to 19 October
2020 (7 of which were also included by Viner et al.
(2020)). They compared the secondary attack rate in each
study and found the summary proportion of participants
with SARS-CoV-2 was higher in adult contacts (28.3%,
95% CI 20.2–37.1%) than in child and adolescent contacts
of all ages (<18 years of age) (16.8%, 95% CI 12.3–21.7%)
[45]. Most of the studies in these reviews were conducted
during times of strict social distancing. There is a risk
of bias in levels of exposure for adults and for children.
Adults were at risk of infection outside their homes, for ex-
ample, while shopping or at work, whilst children stayed
mostly at home. Children were, however, likely in contact
with adults within the families.
Some individual household studies (several of which are
included in the cited systematic reviews) distinguished be-
tween narrower age groups. A cohort study analysing 392
household contacts of 105 index patients in China calcu-
lated secondary attack rates of 2.3% (1/44) for younger
children (aged 0–5 years), 5.4% (3/56) for school children
and adolescents (aged 6–17 years) and 17.1% (60/292) for
adults [46). In Singapore, a household study described 213
children in 134 households, of whom 13 became infect-
ed with SARS-CoV-2: 0–4 years old, 1.3% (1/77); 5–9
years, 8.1% (6/68); and 10–16 years, 9.8% (6/55) [47]. In
households in Israel with large numbers of children, older
children and adolescents (aged 5–17 years) were found to
be 61% less likely to be infected with SARS-CoV-2 than
adults, with the risk for younger children 0–4 years of age
being 47% lower than the risk for adults [48].
Seroprevalence studies
In a nationally representative seroprevalence survey per-
formed during a strict national lockdown in Spain (April-
May 2020), seroprevalence measured by immunoassay and
point-of-care tests was lowest in the youngest age groups
(both tests positive: <1 year: 0%, 95% CI 0.0–11.9%; 1–4
years: 2.6%, 95% CI 1.2–5.5% vs e.g., 20–24 years:
3.7%, 95% CI 2.7–4.9%) [49]. The SEROCoV-POP sero-
prevalence study in Geneva, (>5 years old) in April-May
2020 found a lower risk of antibody positivity for children
<10 years (RR 0.32, 95% CI 0.11–0.65) than for adults >20
years of age. Seroprevalence among children aged 10–19
years was similar to that of >20 year olds (risk ratio 0.86,
95%-CI: 0.57–1.22) [50]. As this was a retrospective study
that was conducted when Swiss schools were closed, in-
dividual sources of infection were not analysed and chil-
dren might have been less exposed to SARS-CoV-2 than
adult household members. Another survey round was done
during a regional lockdown after the second peak of the
pandemic in November-December 2020. Seroprevalence
became similar for school children and adolescents (6–11
year olds: 22.8%, 95% CI 18.7–27.1%; 12–17 year olds:
23.6%, 95% CI 19.6–28.0%) and adults (25–34 years:
25.9%, 95% CI 21.8–30.2%) but was lower for children
aged 0–5 years (14.9%, 95% CI 10.7–19.6%) [51].
In a study in Germany, volunteers were invited through
newspaper and social media adverts and antibody levels
were measured in 5042 parent-child pairs in April-May
2020 during a strict lockdown [52]. A higher proportion
of parents (1.8%, 95% CI 1.3–2.4%) than children (1–5
years, 0.6%, 95% CI 0.3–1.3%) had SARS-CoV-2 antibod-
ies. In Chile, a school outbreak of 52 reverse transcrip-
tion polymerase chain reaction (RT-PCR) test positive cas-
es was analysed and seroprevalence was measured in a
random sample of students and staff 8–10 weeks after the
outbreak. The index case was a staff member in the pre-
school department. The authors thought it likely that the
staff member infected both pre-school children at school
and parents and colleagues during parent-teacher meetings.
They found 16.6% (95% CI 12.1–21.9%) of staff had an-
tibodies. A higher percentage of younger children (pre-
school, 12.3%, 95% CI 7.8–18.6%) than high school stu-
dents (5.7%, 95% CI 3.6–8.9%) had antibodies [53].
Risk of children and adolescents transmitting SARS-
CoV-2
We found a range of relevant study designs, including
laboratory-based studies, seroprevalence studies and sec-
ondary attack rate studies in households or schools/day
care centres. We also analysed studies specifically looking
into the paediatric transmission potential of SARS-CoV-2
variants of concern.
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Laboratory-based studies measuring SARS-CoV-2
Infectious SARS-CoV-2 can be isolated from children as
young as 7 days old. In Geneva, SARS-CoV-2 was suc-
cessfully cultured in samples taken from 12 out of 23 chil-
dren aged <16 years [54]. The same group found compara-
ble viral load levels (inferred from cycle threshold values
in PCR analyses) by age group in laboratory samples taken
within 5 days of symptom onset and tested between March
and May 2020 (53/405 aged <16 years) [55]. In a large lab-
oratory-based study in Germany, researchers analysed cy-
cle threshold values from PCR tests and found an associ-
ation between increasing age and increasing viral load on
one system (Roche Cobas system) and a negative associa-
tion on the other (Roche LC480 system) [56]. An indepen-
dent statistical analysis of the same data found that viral
load increased with age [57]. A major limitation of studies
based on collections of samples in diagnostic laboratories
is that inclusion in a study depends on having been tested.
Since testing for SARS-CoV-2 concentrates on detection
of infection in people with symptoms, children who are in-
cluded in these sample collections are unlikely to be repre-
sentative of all those infected (selection bias).
Seroprevalence studies
A longitudinal seroprevalence study in schools in Zurich,
Switzerland followed children aged 6–16 years in 55
schools and 273 classes in June/July and 275 October/No-
vember during a period when hygienic measures were in
place (e.g., mask wearing for teachers and students >12
years of age). In seven classes in five schools ≥3 students
had SARS-CoV-2 antibodies in periods of moderate to
high community transmission when seroprevalence itself
increased from 2.4% to 4.5% in schools [19]. It is not
known whether the students were infected as part of an out-
break or were sporadic cases, nor whether the infections
were acquired or transmitted in the school.
Secondary attack rate studies in households or
schools / day care centres
A meta-analysis analysing household clusters up to 24 Au-
gust 2020 reported that a child or an adolescent (<18 years)
was identified as the first case in 4% (8/13) of these clus-
ters. The paediatric index cases also led to fewer secondary
cases than adult index cases (4% vs 96% of 398 sec-
ondary cases). Acknowledging the potential undercounting
of children as index cases, the authors included asympto-
matic children as possible index cases and the proportion
of clusters with an index case <18 years increased to 19%
(30/211), and the proportion of secondary cases increased
to 22% (80/395 contacts) [44]. A regularly updated re-
view that includes studies with contact tracing data up to
21 January 2021 reported very limited transmission from
younger children in school settings, but found potential
outbreaks in school children and adolescents (without fur-
ther clarification of the respective age groups), especially
during times of higher community transmission [1].
Several studies have described clusters of SARS-CoV-2 in-
volving schools and school camps. A SARS-CoV-2 out-
break was described in a school in northern France in early
2020. In a serosurvey in one high school seroprevalence
was higher in adolescents (82/205, 40% in 15–17 year
olds) than adults (88/415, 21% in >18 years olds) [58]. As
neither the sampling methodology is known nor were the
supposed index cases laboratory-confirmed SARS-CoV-2
cases, the extent of spread in the school compared with
outside is not known. Further studies describe clusters of
cases in overnight camps / retreats in the US and a school
in Israel [59-61]. Pray et al. (2020) [60] and Stein-Zamir
et al. (2020) (61] describe outbreaks in high schools (ages
12 and older), whereas the camp outbreak described by Sz-
abwlewski et al. (2020) [59] included children and ado-
lescents aged 6–17 years and found similar attack rates in
6–10 year olds (51/100, 51%) and 11–17 year olds (180/
409, 44%).
Other studies from schools have found limited transmis-
sion when community transmission was comparably low
even in secondary education facilities. Potential protective
measures in most reports were not described. Three school
settings in which no child contact became infected were
described in Singapore: 0/8 symptomatic contacts of an in-
fected 12 year old; 0/34 symptomatic contacts of an infect-
ed 5 year old; and 0/77 preschool pupils where a total of
16 staff members were infected [62]. In Australia, 18 index
cases (9 students and 9 teachers) in 15 different schools
(primary and high schools) had close contact with 735 fel-
low students and 128 staff. None of the 128 staff con-
tracted SARS-CoV-2 and the two initial cases (one student
and one staff) only infected two fellow students (one in a
high school and one in a primary school) [63]. In Ireland,
six index cases were described in schools before pre-emp-
tive school closures during the 2020 spring wave. Three
students aged 10–15 years and three adults did not infect
any of the 1001 child contacts tested (924 school contacts,
77 non-school-related contacts) including those with only
mild symptoms [64]. In Germany, 137 index cases aged
<19 years were described from May to August 2020. From
more than 2300 contacts, 11 infections in classmates were
found (3 in childcare facilities, 1 in elementary school, 4
in secondary school and 3 in vocational school). None of
these secondary cases infected any other students. There
were several hygienic control measures in place (e.g., re-
duced class size, exclusion of sick children) [65]. A low
risk of infection from adult and paediatric index cases was
also seen in childcare settings in Rhode Island, USA and in
South Korea [66, 67].
A study from England [68] reported on 177 COVID-19-as-
sociated events in educational settings (preschool, primary
and secondary) involving 130 confirmed cases in children
and 213 in staff members. Most outbreaks (defined as ≥2
linked cases from the same education facility in ≤14 days,
including the index case) were small (median number of
cases 2, interquartile range 2–5). The maximum size of
outbreaks and thus the number of secondary cases was
lower when the index case was a child (median 1, max-
imum 6) than when the index case was a staff member
(median 1, maximum 12). Despite low case numbers there
was a strong association with regional incidence of report-
ed COVID-19; for every 5 new cases per 100,000 inhab-
itants the risk of an outbreak increased by 72% (95% CI
28–130%). In most outbreaks, a staff member was the in-
dex case (staff to staff in 26/55 outbreaks, staff to student
in 8/55 outbreaks, student to staff in 16/55 outbreaks and
student to student in 5/55 outbreaks). The same pattern of
index cases was seen in Georgia, USA, where nine clus-
ters were described in elementary schools from Decem-
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ber 2020 to January 2021. Of these nine clusters four were
started by teachers, one by a student and four were un-
known [69].
Studies on the paediatric transmission risks of new SARS-
CoV-2 variants
The British Children’s Task and Finish Group describes an
increase in infection prevalence between September and
October 2020, which was most marked in the 16–24 year
olds followed by 12–16 year olds [42]. The School Infec-
tion Survey conducted in November 2020 found that, de-
spite more testing, the level of infection in schools was
low even in times of high community transmission (stu-
dents: 1.24%, 95% CI 0.96–1.58%; staff: 1.29%, 95% CI
0.96–1.68%) [42]. This report was written before the in-
creased transmissibility of the alpha-variant (B.1.1.7) was
confirmed and other variants such as the delta-variant
(B.1.617.2) were first described as variants of concern. A
modelling study predicted that under 20 year olds could
have been affected more by this new SARS-CoV-2 variant
than by the previous variants, but this could have resulted
from increased transmission when schools were open dur-
ing a lockdown period, from increased susceptibility or
from increased symptoms leading to more testing [70]. We
did not find any data regarding the paediatric transmission
potential of other SARS-CoV-2 variants.
Discussion
This review summarises evidence from 63 studies about
the potential role of children (≤12 years of age) and adoles-
cents (13–17 years of age) in the SARS-CoV-2 pandemic.
We included 63 studies, most of which were from high-in-
come countries and were published between March 2020
and April 2021.
Strengths and limitations of the review
We summarised the literature with a broad remit, address-
ing both clinical and epidemiological aspects of SARS-
CoV-2 infection in children and adolescents. This review
was performed to provide timely evidence for policymak-
ers in Switzerland. Owing to the time-sensitive nature of
the review, we did not plan to conduct a full systematic re-
view, so there is no written protocol or registration. There
are limitations to this kind of rapid review, but we did
try to reduce some of the risks of bias in traditional nar-
rative reviews. First, we used the same systematic search
up to 21 January 2021 and searched two databases to in-
clude studies published both in peer-reviewed journals and
as preprints to obtain new information with a wide range of
designs as soon as it became available. Second, although
we did not use a published tool to assess the risk of bias
in all studies, we report on methodological limitations of
studies in the text, and the potential consequences for the
findings. Third, we report transparently the information
sources, search dates and methodology. To include more
recent data, we performed a non-systematic literature
search until 29 March 2021. By ending the search at 29
March 2021, the review covers studies that were done be-
fore the circulation of SARS-CoV-2 variants of concern
was widely recognised. We might have missed potentially
relevant literature because we only searched two databases
with a comparatively basic search strategy, only one author
assessed the results of the electronic search and we includ-
ed only studies in English or German. However, we sought
a range of expert opinions about studies to include and dis-
cussed the content and interpretation at length. We tried
to describe findings in different age groups of children,
but many studies did not provide enough information for a
finely stratified analysis.
Interpretation
Severity of SARS-CoV-2 presentation in children and ado-
lescents. Children and adolescents usually present with
milder symptoms of SARS-CoV-2 infection than adults
and are more likely to have an asymptomatic SARS-CoV-2
infection. A majority of children and adolescents in both
hospital-based studies of acute infection and population-
based seroprevalence studies developed symptoms of
COVID-19 [16, 17]. Severe disease was uncommon in
children and adolescents [6, 10–15], even amongst those
with predisposing conditions such as immunosuppression
or cancer [30–36]. Paediatric inflammatory multisystem
syndrome temporally associated with SARS-CoV-2
(PIMS-TS) / multisystem inflammatory syndrome in chil-
dren (MIS-C) is one specific manifestation [37–39]. Our
search period identified only one study of long-term symp-
toms after SARS-CoV-2 infection [40]. Further studies are
being published, however, with researchers from Switzer-
land and from the UK describing a small proportion of
children experiencing symptoms lasting more than 2 to 3
months [71, 72].
Risk of SARS-CoV-2 infection in children and adolescents.
The risk of becoming infected with SARS-CoV-2 is a com-
bination of susceptibility (host biological factors), external
factors associated with exposure type (work, shopping,
schools, etc.) and exposure intensity (level of community
transmission and of preventive measures). Triangulation of
evidence across study designs provides valuable informa-
tion but needs to take into account differences between
countries. In population-based, cross-sectional and sero-
prevalence studies, fewer children than adults were infect-
ed. In the first pandemic wave, when strict lockdowns were
imposed [41, 42], findings might reflect, in part, chil-
dren’s exposure limited to the household while parents had
more contacts outside. In studies in which all household
members were exposed to an infected person, the propor-
tion becoming infected with SARS-CoV-2 also increases
with age [43–47]. Household members might have more
similar levels of exposure, but there are still differences in
intensity of exposure, with spouses likely being more ex-
posed to an infected adult than children [2]. As children
have fewer and milder symptoms than adults, they might
be less likely to be diagnosed as the index case, thus limit-
ing the potential interpretation of this data.
Risk of children and adolescents transmitting SARS-CoV-2.
Studies analysing the secondary attack rate show that chil-
dren can transmit SARS-CoV-2 in households, schools and
day care centres [1, 44, 58–61]. Amongst diagnosed indi-
viduals tested at the same time point after symptom on-
set, estimated SARS-CoV-2 viral load, in one study, was
similar in children, adolescents and adults [55]. Transmis-
sion is, however, also influenced by physiological features
such as lung capacity, hindering direct comparisons. As
with susceptibility to infection, the relative transmissibility
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of SARS-CoV-2 at different ages remains uncertain, large-
ly because of biases in the ascertainment of the challenges
involved in disentangling the influences of biological, host
and environmental factors [7].
The circulation of SARS-CoV-2 variants of concern, with
the alpha variant becoming dominant in Switzerland in
April 2021, and then being rapidly replaced by the delta
variant, may change epidemiology of the infection in chil-
dren and adolescents. Studies done during periods when
SARS-CoV-2 variants of concern are circulating will pro-
vide new information. Studies in outbreak settings can
compare the risks of infection with, and transmission of,
coronavirus for children and adolescents with those of
adults [73]. Large prospective longitudinal studies, with
the same methodology over time, will be needed to deter-
mine whether differences between variants affect children,
adolescents and adults differently.
Conclusion
Children are susceptible to SARS-CoV-2 infection and can
transmit the coronavirus. Susceptibility to, and transmissi-
bility of SARS-CoV-2 appear to be lower in young chil-
dren than in adolescents and adults. Precise levels and
the observed magnitude of age-related differences depend
on more than biological factors, including the level of
community transmission, between age-group differences
in exposure and the stringency of non-pharmaceutical mea-
sures. In laboratory-based and epidemiological studies, re-
searchers should report these factors as part of the context
in which the study was done, so that the findings can be
interpreted more easily. Large, prospective studies that at-
tempt to minimise biases in design, are analysed appro-
priately, and are reported comprehensively should be con-
ducted.
New studies about age-related differences in severity, sus-
ceptibility to, and transmissibility of, SARS-CoV-2 vari-
ants of concern in children and adolescents are needed.
These studies are particularly important as children are a
largely unvaccinated part of the population. Because of the
socioeconomic costs resulting from this lack of informa-
tion, more testing in schools and measures that will reduce
the risk of SARS-CoV-2 transmission in schools should
be considered. Research will allow monitoring of the in-
cidence of SARS-CoV-2 infection among children in the
community, including in the presence of new variants, de-
scribe long-term consequences of infection at the popula-
tion level, and follow-up of vaccination uptake and effec-
tiveness to minimise harms.
Recommendations for future research
In order to improve the significance of future studies we
recommend considering the following aspects to analyse
the role children and adolescents play in this pandemic:
– We recommend selecting the appropriate study design
for the respective research question, for example, per-
form population-based studies instead of hospital-based
studies to analyse the frequency of asymptomatic infec-
tion.
– We recommend studies differentiating between differ-
ent paediatric age groups.
– We recommend performing prospective, longitudinal
studies instead of retrospective studies (e.g., seropreva-
lence studies).
– We recommend performing outbreak studies based on
thorough contact tracing, i.e. to trace all contacts, even
those outside of the respective educational facilities or
households, to properly identify the sources of infec-
tion.
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Hospital Basel, Botnar Foundation Basel, as well as a paid member-
ship for the Scientific advisory Board from the Novartis Institute for
Tropical disease.
Funding
There was no funding source for this study.
References
1. Boast A , Munro A , Goldstein H . An evidence summary of Paediatric
COVID-19 literature. Don't Forget the Bubbles. 2020.
2. Goldstein E , Lipsitch M , Cevik M . On the Effect of Age on the Trans-
mission of SARS-CoV-2 in Households, Schools, and the Community. J
Infect Dis. 2021 Feb;223(3):362–9. http://dx.doi.org/10.1093/infdis/ji-
aa691. PubMed. 1537-6613
3. Hyde Z . COVID-19, children and schools: overlooked and at risk. Med
J Aust. 2020 Nov;213(10):444–446.e1. http://dx.doi.org/10.5694/
mja2.50823. PubMed. 1326-5377
4. Van Lancker W , Parolin Z . COVID-19, school closures, and child
poverty: a social crisis in the making. Lancet Public Health.
2020 May;5(5):e243–4. http://dx.doi.org/10.1016/
S2468-2667(20)30084-0. PubMed. 2468-2667
5. Silverman M , Sibbald R , Stranges S . Ethics of COVID-19-related
school closures. Can J Public Health. 2020 Aug;111(4):462–5.
http://dx.doi.org/10.17269/s41997-020-00396-1. PubMed. 1920-7476
6. Morand A , Fabre A , Minodier P , Boutin A , Vanel N , Bosdure E , et
al. COVID-19 virus and children: what do we know? Arch Pediatr.
2020 Apr;27(3):117–8. http://dx.doi.org/10.1016/j.arcped.2020.03.001.
PubMed. 1769-664X
7. Accorsi EK , Qiu X , Rumpler E , Kennedy-Shaffer L , Kahn R , Joshi K
, et al. How to detect and reduce potential sources of biases in studies of
SARS-CoV-2 and COVID-19. Eur J Epidemiol. 2021 Feb;36(2):179–96.
http://dx.doi.org/10.1007/s10654-021-00727-7. PubMed. 1573-7284
8 Swiss National COVID-19 Science Task Force . The role of children
(≤12 years of age) and adolescents (13-17 years of age) in the SARS-
CoV-2 pandemic: A rapid review. 2021.
9. World Health Organization . COVID-19 Weekly Epidemiological Up-
date. 2021;Edition 41.
10. Liu W , Zhang Q , Chen J , Xiang R , Song H , Shu S , et al. Detection
of Covid-19 in Children in Early January 2020 in Wuhan, China. N Engl
J Med. 2020 Apr;382(14):1370–1. http://dx.doi.org/10.1056/NE-
JMc2003717. PubMed. 1533-4406
Systematic review Swiss Med Wkly. 2021;151:w30058
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution-NonCommercial-ShareAlike 4.0”.
No commercial reuse without permission. See https://smw.ch/permissions
Page 7 of 13
11. Mustafa NM , A Selim L . Characterisation of COVID-19 Pandemic in
Paediatric Age Group: A Systematic Review and Meta-Analysis. J Clin
Virol. 2020 Jul;128:104395. http://dx.doi.org/10.1016/
j.jcv.2020.104395. PubMed. 1873-5967
12. Lu X , Zhang L , Du H , Zhang J , Li YY , Qu J , et al.; Chinese Pedi-
atric Novel Coronavirus Study Team . SARS-CoV-2 Infection in Chil-
dren. N Engl J Med. 2020 Apr;382(17):1663–5. http://dx.doi.org/
10.1056/NEJMc2005073. PubMed. 1533-4406
13. Dong Y , Mo X , Hu Y , Qi X , Jiang F , Jiang Z , et al. Epidemiology
of COVID-19 Among Children in China. Pediatrics.
2020 Jun;145(6):e20200702. http://dx.doi.org/10.1542/peds.2020-0702.
PubMed. 1098-4275
14. Castagnoli R , Votto M , Licari A , Brambilla I , Bruno R , Perlini S , et
al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Infection in Children and Adolescents: A Systematic Review. JAMA
Pediatr. 2020 Sep;174(9):882–9. http://dx.doi.org/10.1001/jamapedi-
atrics.2020.1467. PubMed. 2168-6211
15. Hoang A , Chorath K , Moreira A , Evans M , Burmeister-Morton F ,
Burmeister F , et al. COVID-19 in 7780 pediatric patients: A systematic
review. EClinicalMedicine. 2020 Jun;24:100433. http://dx.doi.org/
10.1016/j.eclinm.2020.100433. PubMed. 2589-5370
16. Buitrago-Garcia D , Egli-Gany D , Counotte MJ , Hossmann S , Imeri H
, Ipekci AM , et al. Occurrence and transmission potential of asympto-
matic and presymptomatic SARS-CoV-2 infections: A living systematic
review and meta-analysis. PLoS Med. 2020 Sep;17(9):e1003346.
http://dx.doi.org/10.1371/journal.pmed.1003346. PubMed. 1549-1676
17. Richard A , Wisniak A , Perez-Saez J , Garrison-Desany H , Petrovic D ,
Piumatti G , et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies,
risk factors for infection and associated symptoms in Geneva, Switzer-
land: a population-based study. medRxiv. 2020.
18. Ulyte A , Radtke T , Abela IA , Haile SR , Blankenberger J , Jung R , et
al. Variation in SARS-CoV-2 seroprevalence across districts, schools
and classes: baseline measurements from a cohort of primary and sec-
ondary school children in Switzerland. BMJ Open.
2021 Jul;11(7):e047483. http://dx.doi.org/10.1136/
bmjopen-2020-047483. PubMed. 2044-6055
19. Ulyte A , Radtke T , Abela IA , Haile SR , Berger C , Huber M , et al.
Clustering and longitudinal change in SARS-CoV-2 seroprevalence in
school children in the canton of Zurich, Switzerland: prospective cohort
study of 55 schools. BMJ. 2021 Mar;372(616):n616. http://dx.doi.org/
10.1136/bmj.n616. PubMed. 1756-1833
20. Bialek S , Gierke R , Hughes M , McNamara LA , Pilishvili T , Skoff T ;
CDC COVID-19 Response Team . Coronavirus Disease 2019 in Chil-
dren - United States, February 12-April 2, 2020. MMWR Morb Mortal
Wkly Rep. 2020 Apr;69(14):422–6. http://dx.doi.org/10.15585/
mmwr.mm6914e4. PubMed. 1545-861X
21. Gordon M , Kagalwala T , Rezk K , Rawlingson C , Ahmed MI , Gu-
leri A . Rapid systematic review of neonatal COVID-19 including a case
of presumed vertical transmission. BMJ Paediatr Open.
2020 May;4(1):e000718. http://dx.doi.org/10.1136/
bmjpo-2020-000718. PubMed. 2399-9772
22. Dumpa V , Kamity R , Vinci AN , Noyola E , Noor A . Neonatal Coron-
avirus 2019 (COVID-19) Infection: A Case Report and Review of Liter-
ature. Cureus. 2020 May;12(5):e8165. PubMed. 2168-8184
23. Sheth S , Shah N , Bhandari V . Outcomes in COVID-19 Positive
Neonates and Possibility of Viral Vertical Transmission: A Narrative Re-
view. Am J Perinatol. 2020 Oct;37(12):1208–16. http://dx.doi.org/
10.1055/s-0040-1714719. PubMed. 1098-8785
24. Kyle MH , Glassman ME , Khan A , Fernández CR , Hanft E ,
Emeruwa UN , et al. A review of newborn outcomes during the
COVID-19 pandemic. Semin Perinatol. 2020 Nov;44(7):151286.
http://dx.doi.org/10.1016/j.semperi.2020.151286. PubMed. 1558-075X
25. Vardhelli V , Pandita A , Pillai A , Badatya SK . Perinatal COVID-19:
review of current evidence and practical approach towards prevention
and management. Eur J Pediatr. 2021 Apr;180(4):1009–31.
http://dx.doi.org/10.1007/s00431-020-03866-3. PubMed. 1432-1076
26. Wei M , Yuan J , Liu Y , Fu T , Yu X , Zhang ZJ . Novel Coronavirus In-
fection in Hospitalized Infants Under 1 Year of Age in China. JAMA.
2020 Apr;323(13):1313–4. http://dx.doi.org/10.1001/jama.2020.2131.
PubMed. 1538-3598
27. Zhang ZJ , Yu XJ , Fu T , Liu Y , Jiang Y , Yang BX , et al. Novel coro-
navirus infection in newborn babies aged <28 days in China. Eur Respir
J. 2020 Jun;55(6):2000697. http://dx.doi.org/10.1183/
13993003.00697-2020. PubMed. 1399-3003
28. Gale C , Quigley MA , Placzek A , Knight M , Ladhani S , Draper ES ,
et al. Characteristics and outcomes of neonatal SARS-CoV-2 infection
in the UK: a prospective national cohort study using active surveillance.
Lancet Child Adolesc Health. 2021 Feb;5(2):113–21. http://dx.doi.org/
10.1016/S2352-4642(20)30342-4. PubMed. 2352-4650
29. Swann OV , Holden KA , Turtle L , Pollock L , Fairfield CJ , Drake TM
, et al.; ISARIC4C Investigators . Clinical characteristics of children and
young people admitted to hospital with covid-19 in United Kingdom:
prospective multicentre observational cohort study. BMJ.
2020 Aug;370:m3249. http://dx.doi.org/10.1136/bmj.m3249. PubMed.
1756-1833
30. Balduzzi A , Brivio E , Rovelli A , Rizzari C , Gasperini S , Melzi ML ,
et al. Lessons after the early management of the COVID-19 outbreak in
a pediatric transplant and hemato-oncology center embedded within a
COVID-19 dedicated hospital in Lombardia, Italy. Estote parati. Bone
Marrow Transplant. 2020 Oct;55(10):1900–5. http://dx.doi.org/10.1038/
s41409-020-0895-4. PubMed. 1476-5365
31. Ferrari A , Zecca M , Rizzari C , Porta F , Provenzi M , Marinoni M , et
al. Children with cancer in the time of COVID-19: An 8-week report
from the six pediatric onco-hematology centers in Lombardia, Italy. Pe-
diatr Blood Cancer. 2020 Aug;67(8):e28410. http://dx.doi.org/10.1002/
pbc.28410. PubMed. 1545-5017
32. Marlais M , Wlodkowski T , Vivarelli M , Pape L , Tönshoff B , Schae-
fer F , et al. The severity of COVID-19 in children on immunosuppres-
sive medication. Lancet Child Adolesc Health. 2020 Jul;4(7):e17–8.
http://dx.doi.org/10.1016/S2352-4642(20)30145-0. PubMed. 2352-4650
33. Boulad F , Kamboj M , Bouvier N , Mauguen A , Kung AL . COVID-19
in Children With Cancer in New York City. JAMA Oncol.
2020 Sep;6(9):1459–60. http://dx.doi.org/10.1001/jamaon-
col.2020.2028. PubMed. 2374-2445
34. Hrusak O , Kalina T , Wolf J , Balduzzi A , Provenzi M , Rizzari C , et
al. Flash survey on severe acute respiratory syndrome coronavirus-2 in-
fections in paediatric patients on anticancer treatment. Eur J Cancer.
2020 Jun;132:11–6. http://dx.doi.org/10.1016/j.ejca.2020.03.021.
PubMed. 1879-0852
35. Minotti C , Tirelli F , Barbieri E , Giaquinto C , Donà D . How is im-
munosuppressive status affecting children and adults in SARS-CoV-2
infection? A systematic review. J Infect. 2020 Jul;81(1):e61–6.
http://dx.doi.org/10.1016/j.jinf.2020.04.026. PubMed. 1532-2742
36. Rawson A , Wilson AC , Schwaderer AL , Spiwak E , Johnston B , An-
derson S , et al. Coronavirus disease 2019 (COVID-19) in two pediatric
patients with kidney disease on chronic immunosuppression: A case se-
ries. Hemodial Int. 2021 Jan;25(1):E1–5. http://dx.doi.org/10.1111/
hdi.12876. PubMed. 1542-4758
37. Jones VG , Mills M , Suarez D , Hogan CA , Yeh D , Segal JB , et al.
COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. Hosp
Pediatr. 2020 Jun;10(6):537–40. http://dx.doi.org/10.1542/
hpeds.2020-0123. PubMed. 2154-1671
38. Riphagen S , Gomez X , Gonzalez-Martinez C , Wilkinson N ,
Theocharis P . Hyperinflammatory shock in children during COVID-19
pandemic. Lancet. 2020 May;395(10237):1607–8. http://dx.doi.org/
10.1016/S0140-6736(20)31094-1. PubMed. 1474-547X
39. Dufort EM , Koumans EH , Chow EJ , Rosenthal EM , Muse A , Row-
lands J , et al.; New York State and Centers for Disease Control and Pre-
vention Multisystem Inflammatory Syndrome in Children Investigation
Team . Multisystem Inflammatory Syndrome in Children in New York
State. N Engl J Med. 2020 Jul;383(4):347–58. http://dx.doi.org/10.1056/
NEJMoa2021756. PubMed. 1533-4406
40. Buonsenso D , Munblit D , De Rose C , Sinatti D , Ricchiuto A , Carfi A
, et al. Preliminary evidence on long COVID in children. Acta Paediatr.
2021 Jul;110(7):2208–11. http://dx.doi.org/10.1111/apa.15870.
PubMed. 1651-2227
41. Lavezzo E , Franchin E , Ciavarella C , Cuomo-Dannenburg G , Bar-
zon L , Del Vecchio C , et al.; Imperial College COVID-19 Response
Team; Imperial College COVID-19 Response Team . Suppression of a
SARS-CoV-2 outbreak in the Italian municipality of Vo’. Nature.
2020 Aug;584(7821):425–9. http://dx.doi.org/10.1038/
s41586-020-2488-1. PubMed. 1476-4687
42 Children’s Task and Finish Group. Children’s Task and Finish Group :
update to 4th Nov 2020 paper on children, schools and transmission.
2020.
43. Viner RM , Mytton OT , Bonell C , Melendez-Torres GJ , Ward J , Hud-
son L , et al. Susceptibility to SARS-CoV-2 Infection Among Children
and Adolescents Compared With Adults: A Systematic Review and
Meta-analysis. JAMA Pediatr. 2021 Feb;175(2):143–56.
http://dx.doi.org/10.1001/jamapediatrics.2020.4573. PubMed.
2168-6211
44. Zhu Y , Bloxham CJ , Hulme KD , Sinclair JE , Tong ZW , Steele LE ,
et al. A meta-analysis on the role of children in SARS-CoV-2 in house-
hold transmission clusters. Clin Infect Dis. 2020.1058-4838
45. Madewell ZJ , Yang Y , Longini IM Jr , Halloran ME , Dean NE .
Household Transmission of SARS-CoV-2: A Systematic Review and
Meta-analysis. JAMA Netw Open. 2020 Dec;3(12):e2031756.
Systematic review Swiss Med Wkly. 2021;151:w30058
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution-NonCommercial-ShareAlike 4.0”.
No commercial reuse without permission. See https://smw.ch/permissions
Page 8 of 13
http://dx.doi.org/10.1001/jamanetworkopen.2020.31756. PubMed.
2574-3805
46. Li W , Zhang B , Lu J , Liu S , Chang Z , Peng C , et al. Characteristics
of Household Transmission of COVID-19. Clin Infect Dis.
2020 Nov;71(8):1943–6. http://dx.doi.org/10.1093/cid/ciaa450.
PubMed. 1537-6591
47. Yung CF , Kam KQ , Chong CY , Nadua KD , Li J , Tan NW , et al.
Household Transmission of Severe Acute Respiratory Syndrome Coro-
navirus 2 from Adults to Children. J Pediatr. 2020 Oct;225:249–51.
http://dx.doi.org/10.1016/j.jpeds.2020.07.009. PubMed. 1097-6833
48. Somekh E , Gleyzer A , Heller E , Lopian M , Kashani-Ligumski L ,
Czeiger S , et al. The Role of Children in the Dynamics of Intra Family
Coronavirus 2019 Spread in Densely Populated Area. Pediatr Infect Dis
J. 2020 Aug;39(8):e202–4. http://dx.doi.org/10.1097/
INF.0000000000002783. PubMed. 1532-0987
49. Pollán M , Pérez-Gómez B , Pastor-Barriuso R , Oteo J , Hernán MA ,
Pérez-Olmeda M , et al.; ENE-COVID Study Group . Prevalence of
SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based
seroepidemiological study. Lancet. 2020 Aug;396(10250):535–44.
http://dx.doi.org/10.1016/S0140-6736(20)31483-5. PubMed. 1474-547X
50. Stringhini S , Wisniak A , Piumatti G , Azman AS , Lauer SA ,
Baysson H , et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies
in Geneva, Switzerland (SEROCoV-POP): a population-based study.
Lancet. 2020 Aug;396(10247):313–9. http://dx.doi.org/10.1016/
S0140-6736(20)31304-0. PubMed. 1474-547X
51. Stringhini S , Zaballa ME , Perez-Saez J , Pullen N , de Mestral C , Pi-
cazio A , et al.; Specchio-COVID19 Study Group . Seroprevalence of
anti-SARS-CoV-2 antibodies after the second pandemic peak. Lancet In-
fect Dis. 2021 May;21(5):600–1. http://dx.doi.org/10.1016/
S1473-3099(21)00054-2. PubMed. 1474-4457
52 Debatin K-M , Henneke P , Hoffmann GF , Kräusslich H-G . Prevalence
of COVID-19 in children in Baden-Württemberg - Preliminary study re-
port. 2020.
53. Torres JP , Pinera C , De La Maza V , Lagomarcino AJ , Simian D , Tor-
res B , et al. SARS-CoV-2 antibody prevalence in blood in a large
school community subject to a Covid-19 outbreak: a cross-sectional
study. Clin Infect Dis. 2021;73(2):e458–65. http://dx.doi.org/10.1093/
cid/ciaa955. PubMed. 1058-4838
54. L’Huillier AG , Torriani G , Pigny F , Kaiser L , Eckerle I . Culture-
Competent SARS-CoV-2 in Nasopharynx of Symptomatic Neonates,
Children, and Adolescents. Emerg Infect Dis. 2020 Oct;26(10):2494–7.
http://dx.doi.org/10.3201/eid2610.202403. PubMed. 1080-6059
55. Baggio S , L’Huillier AG , Yerly S , Bellon M , Wagner N , Rohr M , et
al. SARS-CoV-2 viral load in the upper respiratory tract of children and
adults with early acute COVID-19. Clin Infect Dis. 2020. PubMed.
1058-4838
56. Jones TC , Mühlemann B , Veith T , Biele G , Zuchowski M , Hof-
mann J , et al. An analysis of SARS-CoV-2 viral load by patient
age. medRxiv. 2020:2020.06.08.20125484. http://dx.doi.org/10.1101/
2020.06.08.20125484.
57 Held L. A discussion and reanalysis of the results reported in Jones et al.
(2020). 2020.
58. Fontanet A , Tondeur L , Madec Y , Grant R , Besombes C , Jolly N , et
al. Cluster of COVID-19 in northern France: A retrospective closed co-
hort study. medRxiv. 2020:2020.04.18.20071134.
59. Szablewski CM , Chang KT , Brown MM , Chu VT , Yousaf AR ,
Anyalechi N , et al. SARS-CoV-2 Transmission and Infection Among
Attendees of an Overnight Camp - Georgia, June 2020. MMWR Morb
Mortal Wkly Rep. 2020 Aug;69(31):1023–5. http://dx.doi.org/10.15585/
mmwr.mm6931e1. PubMed. 1545-861X
60. Pray IW , Gibbons-Burgener SN , Rosenberg AZ , Cole D , Borenstein S
, Bateman A , et al. COVID-19 Outbreak at an Overnight Summer
School Retreat - Wisconsin, July-August 2020. MMWR Morb Mortal
Wkly Rep. 2020 Oct;69(43):1600–4. http://dx.doi.org/10.15585/
mmwr.mm6943a4. PubMed. 1545-861X
61. Stein-Zamir C , Abramson N , Shoob H , Libal E , Bitan M , Cardash T ,
et al. A large COVID-19 outbreak in a high school 10 days after
schools’ reopening, Israel, May 2020. Euro Surveill. 2020 Jul;25(29).
http://dx.doi.org/10.2807/1560-7917.ES.2020.25.29.2001352. PubMed.
1560-7917
62. Yung CF , Kam KQ , Nadua KD , Chong CY , Tan NW , Li J , et al.
Novel Coronavirus 2019 Transmission Risk in Educational Settings.
Clin Infect Dis. 2021 Mar;72(6):1055–8. http://dx.doi.org/10.1093/cid/
ciaa794. PubMed. 1537-6591
63 The National Centre for Immunisation Research and Surveillance
(NCIRS) . COVID-19 in schools – the experience in NSW. 2020.
64. Heavey L , Casey G , Kelly C , Kelly D , McDarby G . No evidence of
secondary transmission of COVID-19 from children attending school in
Ireland, 2020. Euro Surveill. 2020 May;25(21). http://dx.doi.org/
10.2807/1560-7917.ES.2020.25.21.2000903. PubMed. 1560-7917
65. Ehrhardt J , Ekinci A , Krehl H , Meincke M , Finci I , Klein J , et al.
Transmission of SARS-CoV-2 in children aged 0 to 19 years in child-
care facilities and schools after their reopening in May 2020, Baden-
Württemberg, Germany. Euro Surveill. 2020 Sep;25(36).
http://dx.doi.org/10.2807/1560-7917.ES.2020.25.36.2001587. PubMed.
1560-7917
66. Link-Gelles R , DellaGrotta AL , Molina C , Clyne A , Campagna K ,
Lanzieri TM , et al. Limited Secondary Transmission of SARS-CoV-2
in Child Care Programs - Rhode Island, June 1-July 31, 2020. MMWR
Morb Mortal Wkly Rep. 2020 Aug;69(34):1170–2. http://dx.doi.org/
10.15585/mmwr.mm6934e2. PubMed. 1545-861X
67. Yoon Y , Choi GJ , Kim JY , Kim KR , Park H , Chun JK , et al. Child-
care Exposure to Severe Acute Respiratory Syndrome Coronavirus 2 for
4-Year-Old Presymptomatic Child, South Korea. Emerg Infect Dis.
2021 Feb;27(2):341–7. http://dx.doi.org/10.3201/eid2702.203189.
PubMed. 1080-6059
68. Ismail SA , Saliba V , Lopez Bernal J , Ramsay ME , Ladhani SN .
SARS-CoV-2 infection and transmission in educational settings: a
prospective, cross-sectional analysis of infection clusters and outbreaks
in England. Lancet Infect Dis. 2021 Mar;21(3):344–53.
http://dx.doi.org/10.1016/S1473-3099(20)30882-3. PubMed. 1474-4457
69. Gold JA , Gettings JR , Kimball A , Franklin R , Rivera G , Morris E , et
al.; Georgia K–12 School COVID-19 Investigation Team . Clusters of
SARS-CoV-2 Infection Among Elementary School Educators and Stu-
dents in One School District - Georgia, December 2020-January 2021.
MMWR Morb Mortal Wkly Rep. 2021 Feb;70(8):289–92.
http://dx.doi.org/10.15585/mmwr.mm7008e4. PubMed. 1545-861X
70. Volz E , Mishra S , Chand M , Barrett JC , Johnson R , Geidelberg L , et
al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights
from linking epidemiological and genetic data. medRxiv.
2021:2020.12.30.20249034.
71. Radtke T , Ulyte A , Puhan MA , Kriemler S . Long-term Symptoms Af-
ter SARS-CoV-2 Infection in Children and Adolescents. JAMA.
2021 Jul. http://dx.doi.org/10.1001/jama.2021.11880. PubMed.
1538-3598
72. Molteni E , Sudre CH , Canas LS , Bhopal SS , Hughes RC , Antonel-
li M , et al. Illness duration and symptom profile in symptomatic UK
school-aged children tested for SARS-CoV-2. Lancet Child Adolesc
Health. 2021 Aug;S2352-4642(21)00198-X. PubMed. 2352-4650
73. Loenenbach A , Markus I , Lehfeld AS , An der Heiden M , Haas W ,
Kiegele M , et al. SARS-CoV-2 variant B.1.1.7 susceptibility and infec-
tiousness of children and adults deduced from investigations of child-
care centre outbreaks, Germany, 2021. Euro Surveill. 2021 May;26(21).
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.21.2100433. PubMed.
1560-7917
Systematic review Swiss Med Wkly. 2021;151:w30058
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution-NonCommercial-ShareAlike 4.0”.
No commercial reuse without permission. See https://smw.ch/permissions
Page 9 of 13
Appendix
Systematic review Swiss Med Wkly. 2021;151:w30058
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution-NonCommercial-ShareAlike 4.0”.
No commercial reuse without permission. See https://smw.ch/permissions
Page 10 of 13
Table S1:
Summary of characteristics of studies included in the review.
Author Study type Country Number of study par-
ticipants






Baggio, S. et al. (2020) Cohort
study
Switzerland 53 <16 y old, 352 ≥16 y
old
0-82y n/a Laboratory-based study among symptomatic chil-
dren and adults
Balduzzi, A. et al. (2020) Case re-
port
Italy 5 not reported n/a Observational report in a paediatric haemato-on-
cology department
Boast, A. et al. (2021) Systematic
review
n/a n/a n/a not reported Rapid literature review of paediatric literature
Boulad, F. et al. (2020) Cross-sec-
tional study
USA 20 children, 13 care-
givers
not reported n/a Observational study in a paediatric hemato-oncol-
ogy department




n/a n/a n/a 94 Living systematic review and meta-analysis on
asymptomatic/presymptomatic infections
Buonsenso, D. et al. (2020) Cross-sec-
tional study
Italy 129 children mean 11 ± 4.4y n/a Observational study in children with confirmed
SARS-CoV-2 infection
Castagnoli, R. et al. (2020) Systematic
Review






USA 2572 0-17y n/a National observational study in children with
SARS-CoV-2 infection





UK n/a n/a n/a Review of available data on children, schools and
transmission in UK
Debatin, K.-M. et al. (2020) Cross-sec-
tional study
Germany 2466 children, 2466 cor-
responding parents
0-10y for children n/a Seroprevalence study in children and parents (in-
terim analysis)
Dong, Y. et al. (2020) Cross-sec-
tional study
China 2135 n/a n/a Nationwide observational study of confirmed and
suspected paediatric cases
Dufort, E. M. et al. (2020) Case re-
port
USA 99 0-20y n/a Observational report of confirmed and suspected
paediatric cases




n/a n/a n/a 8 Case report and narrative review on SARS-CoV-2
infection in neonates
Ehrhardt, J. et al. (2020) Cross-sec-
tional study
Germany 137 index cases, >2300
contacts
0-19y n/a Observational study in SARS-CoV-2 infected chil-
dren attending daycare/school and their contacts
to evaluate transmission
Ferrari, A. et al. (2020) Case re-
port
Italy 21 0-18y n/a Observational report in a paediatric haemato-on-
cology departments
Fontanet, A. et al. (2020) Cohort
study
France 326 adolescents and
school staff, 345 parents
and siblings
not reported n/a Retrospective cohort of high-school students, their
families and school staff (COVID19 cluster)
Gale, C. et al. (2020) Cohort
study
UK 66 0-30 days n/a National observational study in neonates with
SARS-CoV-2 infection
Gold, J. A. W. et al. (2020) Case re-
port
USA 32 children, 13 educa-
tors
not reported n/a Observational report of SARS-CoV-2 infections in
students and teachers (COVID19 clusters)
Gordon, M. et al. (2020) Systematic
Review
n/a n/a n/a 8 Rapid literature review of neonatal SARS-CoV-2
infections
Heavey, L. et al. (2020) Case re-
port
Ireland 6 index cases (3 children
and 3 staff members),
1025 contacts
not reported n/a Observational study in SARS-CoV-2 infected chil-
dren attending school and school staff to evaluate
transmission
Held, L. (2020) Narrative
Review/
Viewpoint
n/a n/a n/a n/a Reanalysis of data presented in ref Jones, TC et
al (2020)
Hoang, A. et al. (2020) Systematic
Review
n/a 7780 children n/a 131 Systematic review of studies on children with con-
firmed SARS-CoV-2 infection




200 children not reported n/a Multinational survey in a paediatric hemato-oncol-
ogy departments
Ismail, S. A. et al. (2020) Cohort
study
UK 928 000 (median student
number)
0-18y n/a Observational study of SARS-CoV-2 infection
clusters and outbreaks in schools
Jones, T.C. et al. (2020) Case re-
port
Germany 5524 children tested 0-19y n/a Laboratory study of routine testing samples for
SARDCoV2
Jones, V.G. et al. (2020) Case re-
port
USA 1 0.5y n/a Case report describing Kawasaki-like syndrome in
an infant
Kyle, M.H. et al. (2020) Narrative
Review/
Viewpoint
n/a 35 newborns 17 Review of studies reporting on children born by
mothers with SARS-CoV-2 infection
L‘Huillier, A.G. et al. (2020) Case re-
port
Switzerland 23 median 2y (IQR
3.8–14.5y)
n/a Laboratory based study on children infected by
SARS-CoV-2
Lavezzo, E. et al. (2020) Cross-sec-
tional study
Italy 234 children 0-10 y,
28907 overall
all age groups n/a Population based study
Li, W.B. et al. (2020) Case re-
port
China 105 index cases, 392
household contacts
median 51y (IQR 39-60y) n/a Observational study to evaluate household trans-
mission
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Link-Gelles, R. et al. (2020) Cohort
study
USA 30 pediatric cases, 22
adult cases
not reported n/a Statewide observational program in child care pro-
grams to identify SARS-CoV-2 infections
Liu, W. et al. (2020) Cross-sec-
tional study
China 366 0-16y n/a Observational report in children with SARS-CoV-2
infection
Lu, X. et al. (2020) Case re-
port
China 171 0-16y n/a Observational report in children with SARS-CoV-2
infection
Madewell et al. (2020) Systematic
Review
n/a 77758 Children, <18 y Adults,
≥18y
54 Systematic review of studies on household trans-
mission




18 6-14y n/a Observational study in immunosuppressed chil-
dren with SARS-CoV-2 infections
Minotti et al. (2020) Systematic
Review
n/a 4 children, 106 adults not reported 16 Systematic review of studies in immunosup-
pressed children and adults with SARS-CoV-2 in-
fection
Morand et al. (2020) Narrative
review/
viewpoint
n/a n/a n/a n/a Narrative review about SARS-CoV-2 infection in
children
Mustafa, N. M. et al. (2020) Systematic
review
n/a n/a n/a 17 Systematic review of studies describing clinical
picture and transmission of SARS-CoV-2 in chil-
dren
National Centre for Immuni-




Australia 863 not reported n/a Observational study evaluating transmission be-
tween SARS-CoV-2 infected school children and
staff and their contacts
Pollan, M. et al. (2020) Cross-sec-
tional study
Spain 6627 children, 45331
adults
all age groups n/a Nationwide population based seroprevalence
study
Pray, I. W. et al. (2020) Cross-sec-
tional study
USA 127 children and 25 staff
members
14-45y n/a Observational study about a summer school out-
break
Rawson, A. et al. (2020) Case re-
port
USA 2 13y and 18y n/a Observational report of immunosuppressed chil-
dren with SARS-CoV-2 infections
Richard, A. et al. (2020) Cross-sec-
tional study
Switzerland 902 children, 7442 adults 5-94y n/a Population based seroprevalence survey
Riphagen, S. et al. (2020) Case re-
port
UK 8 6-14y n/a Observation report of Kawasaki-like syndrome in
children with SARS-CoV-2 infection





newborns 39 Review of studies reporting on children born by
mothers with SARS-CoV-2 infection
Somekh, E. et al. (2020) Case re-
port
Israel 58 children, 36 adults 6-48y n/a Observational study on identified family clusters of
SARS-CoV-2 infection
Stein-Zamir, C. et al. (2020) Cross-sec-
tional study
Israel 1164 students, 152 staff ≥12y n/a Observational study about a high school outbreak
Stringhini, S. et al. (2020) Cross-sec-
tional study
Switzerland 455 children, 2311 adults ≥5y n/a Population based seroprevalence study
Stringhini, S. et al. (2021) Cross-sec-
tional study
Switzerland 1014 children, 2986
adults
all age groups n/a Population based seroprevalence study
Swann, O.V. et al. (2020) Cohort
study
UK 651 median 4.6y (IQR
0.3-13.7y)
n/a Observational cohort study in 260 hospitals de-
scribing characteristics of hospitalised children in-
fected with SARS-CoV-2




USA 344 children and staff 6-19y for campers,
14-59y for staff
n/a Observational study about a camp outbreak
Torres, J.P. et al. (2020) Cross-sec-
tional study
Chile 1009 students, 235 staff Mean 10.8y (SD 4.1) for
students, mean 42.8y (SD
10.4) for staff
n/a Observational study about a school outbreak
Ulyte, A. et al. (2021) Cohort
study
Switzerland 2831 students 6-16y n/a Seroprevalence study in school children
Ulyte, A. et al. (2021) Cohort
study
Switzerland 2585 students 6-16y n/a Seroprevalence study in school children
Vardhelli, V. et al. (2020) Systematic
review
n/a 793 neonates newborns 45 Systematic review of studies reporting on children
born by mothers with SARS-CoV-2 infection
Viner, R. M. et al. (2020) Systematic
review
n/a 41640 n/a 32 Systematic review on susceptibility and transmis-
sion of children to SARS-CoV-2 compared to
adults
Volz, E. et al. (2020) Modelling
study
UK n/a n/a n/a Modelling study about the B 1.1.7 variant of
SARS-CoV-2
Wei, M. et al. (2020) Cross-sec-
tional study
China 9 0-1y n/a Observational study in hospitalised infants with
SARS-CoV-2 infection




1 index case, 190 con-
tacts
4y n/a Observational study examining transmission of
SARS-CoV-2 from infected toddler to contacts
Yung, C.F. et al. (2020) Case re-
port
Singapore 223 adult index patients,
213 child contacts
0-16y for children n/a Observational study examining household trans-
mission of SARS-CoV-2 from adults to children
Yung, C.F. et al. (2021) Case re-
port
Singapore 3 index cases (2 pedi-
atric, 1 adult), 119 con-
tacts
5y, 12y n/a Nationwide contact surveillance and contact trac-
ing study on SARS-CoV-2 infections in schools
Zhang, Z.J. et al. (2020) Case re-
port
China 4 0-28 days n/a Observational report of neonates with SARS-
CoV-2 infection
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213 clusters n/a 57 Meta-analysis of studies describing household
transmission clusters of SARS-CoV-2
Abbreviations: IQR, interquartile range; n/a, not applicable
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